نمونه ترجمه تخصصی پزشکی درباره شیمی درمانی در بیماران مبتلا به عود سرطان تخمدان

chemotherapy in patients with ovarian carcinoma recurrence

As the second top malignant in women, ovarian carcinoma kills 150000 women in the world every year [1]. Five years survival rate of the patients is 45% [2]. Prevalence of the disease in Iceland, black people, and Spain is 9.2, 9.4, 10.3 per 100 thousand respectively [3, 4]. In general, ovarian carcinoma is the seventh common type of cancer in women. In 2018, ovarian carcinoma was responsible for 4.4% of total cancer mortality in women. While the disease is more prevalent in the countries with high development index (HDI), the mortality rate is lower in these countries. There are different factors in emergence of ovarian carcinoma. Among them, genetic factor is one of the key ones. Pregnancy, breastfeeding, and contraceptives can help decreasing the risk of the disease. Early diagnosis and prevention are not easy due to the heterogeny nature of the disease [5, 6]. The majority of patients with ovarian carcinoma experience recurrence of the disease during the first three years of the disease [10, 16]. During the recurrence, surgery and chemotherapy are the main treatment approaches [17]. Chemotherapy treatments based on platin are among the most common treatment for this cancer. However, using the drug in long-run creates drug resistance [55]. Although, the disease is affected by platinum in early stages of the treatment, it gradually develops resistance to the medication [25]. Given the gravity of platin resistance, the present review study is an attempt to examine the position of platinum and non-platinum chemotherapy in patients with recurrence of platin-resistant ovarian carcinoma.